JB Pharma Q4 Results: Net profit rises 4% to Rs 88 crore
Operating cash flow improved in FY23 to Rs 626 crores as compared to Rs 170 crores in FY22, strongly aided by the higher proportion of India business and a strong focus on working capital management, which includes inventory and receivables.
Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.
